In the following report, we discuss the potential use of PD-L1 expression in different blood components as a predictive biomarker for anti-PD-(L)1 immunotherapy with a focus on addressing the mechanistic and technical challenges that are based on our understanding of the heterogeneity and complexity of the PD-L1 regulation in cancer cells and immune cells. The gene discussed is CD274; the disease is cancer.